Trial Profile
A Phase 2a Multicenter, Double-blinded, Randomized Trial to Evaluate The Effect of HerpV on Viral Shedding in Adults With Recurrent Genital Herpes.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Herpes simplex vaccine (Primary) ; QS 21
- Indications Herpes genitalis; Herpes simplex virus type 2 infections
- Focus Therapeutic Use
- Sponsors Agenus
- 23 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 May 2014 Planned End Date changed from 1 Feb 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov.
- 07 Nov 2013 Results published in the Media Release.